Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teysuno (S-1) with Epirubicin and Oxaliplatin in Advanced Solid Tumors
NCT02867397Phase 1Completed
- Sponsor
- Disphar
- Start
- Jan 2012
- Primary completion
- Aug 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of tegafur in solid tumor, sponsored by Disphar. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Jan 2012; status: completed.
02
Drugs
tegafur
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02867397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02867397.